Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
20 April 2021 - 8:30PM
Business Wire
Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees
with the European Commission’s Directorate-General for
Competition’s decision to review Illumina’s acquisition of GRAIL, a
company founded to accelerate early screening of cancer. Illumina
will continue to work with the Directorate-General to bring the
investigation to conclusion. Illumina remains committed to the
transaction, the impact of which would accelerate the adoption of a
multi-cancer early detection blood test.
“Reuniting GRAIL and Illumina will allow us to bring GRAIL’s
breakthrough early detection multi-cancer test to patients across
the world faster and consequently save lives,” said Francis
deSouza, Chief Executive Officer of Illumina. “We do not believe
that the European authorities have jurisdiction to review the GRAIL
acquisition and look forward to resolving this matter
expeditiously.”
Illumina originally founded GRAIL five years ago and the two
companies do not compete in any way. In reuniting the two
organizations, Illumina will leverage its global scale of
manufacturing and clinical capabilities, as well as its global
regulatory and reimbursement expertise, to bring early-stage,
multi-cancer testing to patients more quickly and more affordably,
resulting in more lives being saved.
Illumina strongly believes that acquiring GRAIL is in the best
interest of patients, is procompetitive, and benefits the
multi-cancer early detection field as a whole. Together with GRAIL,
Illumina looks forward to changing the course of cancer detection
and treatment.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit www.illumina.com and connect with us on Twitter,
Facebook, LinkedIn, Instagram, and YouTube.
Use of forward-looking statements This release may
contain forward-looking statements that involve risks and
uncertainties. Among the important factors to which our business is
subject that could cause actual results to differ materially from
expectations or guidance contained in any forward-looking
statements are: (i) changes in the rate of growth in the markets we
serve; (ii) the volume, timing and mix of customer orders among our
products and services; (iii) the outcome of the pending acquisition
of GRAIL, Inc.; (iv) challenges inherent in developing,
manufacturing, and launching new products and services; (v) our
ability to obtain regulatory clearance for our products from
government agencies, together with other factors detailed in our
filings with the Securities and Exchange Commission, including our
most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which
are released beforehand. We undertake no obligation, and do not
intend, to update these forward-looking statements, to review or
confirm analysts’ expectations, or to provide interim reports or
updates on the progress of the current quarter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210420005623/en/
Investors: Juliet Cunningham 858.200.6583
ir@illumina.com
Media: Dr. Karen Birmingham EMEA: +44 7500 105665 US:
646.355.2111 kbirmingham@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2024 to May 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2023 to May 2024